Neuropeptides and their receptors in the immune system

Annals of Medicine

Volumn 31, Issue SUPPL. 2, 1999, Pages 15-22

  Van Hagen, P Martin ^a,b   Hofland, Leo J ^a   Ten Bokum, Annemiek M C ^a   Lichtenauer Kaligis, Elgin G R ^a   Kwekkeboom, Dik J ^a   Ferone, Diego ^a   Lamberts, Steven W J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Immune system; Somatostatin; Substance P

Indexed keywords

NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROTRANSMITTER; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SUBSTANCE P; SUBSTANCE P RECEPTOR;

ANIMAL CELL; CONFERENCE PAPER; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MOUSE; NEUROENDOCRINOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT;

AUTOIMMUNE DISEASES; HUMANS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, NEUROKININ-1; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SUBSTANCE P;

EID: 0032731365     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (76)

1. Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495-501.
2. Reichlin S. Somatostatin (second of two parts). N Engl J Med 1983; 309: 1556-63.
3. Krulich I, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968; 83: 783-90.
4. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9.
5. Schönbrunn A, Tashjian H Jr. Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J Biol Chem 1978; 253: 6473-83.
6. Reubi JC, Krenning EP, Lamberts SWJ, Kvols LK. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 1990; 37: 1073-7.
7. Reubi JC, Kvols LK, Krenning EP, Lamberts SWJ. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990; 39 Suppl 2: 78-81.
8. Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB. All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 1994; 198: 605-12.
9. Koch BD, Blalock JB, Schönbrunn A. Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. I. An increase in potassium conductance is responsible for both the hyperpolarization and the decrease in intracellular free calcium produced by somatostatin. J Biol Chem 1988; 263: 216-25.
10. Koch BD, Schönbrunn A. Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. II. An increase in potassium conductance initiates somatostatin-induced inhibition of prolactin secretion. J Biol Chem 1988; 263: 226-34.
11. Lewis DL, Weight FF, Luini A. A guanine nucleotide-binding protein mediates the inhibition of voltage-dependent calcium current by somatostatin in a pituitary cell line. Proc Natl Acad Sci U S A 1986; 83: 9035-9.
12. Ikeda SR, Schofield GG. Somatostatin blocks a calcium current in rat sympathetic ganglion neurones. J Physiol 1989; 409: 221-40.
13. Liebow C, Reilly C, Serrano M, Schally AV. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A 1989; 86: 2003-7.
14. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998; 282: 737-40.
15. Bhathena SJ, Louie J, Schechter GP, Redman RS, Wahl L, Recant L. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes 1981; 30: 127-31.
16. Hiruma K, Koike T, Nakamura H, Sumida T, Maeda T, Tomioka H, et al. Somatostatin receptors on human lymphocytes and leukaemia cells. Immunology 1990; 71: 480-5.
17. Scicchitano R, Dazin P, Bienenstock J, Payan DG, Stanisz AM. Distribution of somatostatin receptors on murine spleen and Peyer's patch T and B lymphocytes. Brain Behav Immun 1987; 1: 173-84.
18. Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989; 264: 949-52.
19. Nakamura H, Koike T, Hiruma K, Sato T, Tomioka H, Yoshida S. Identification of lymphoid cell lines bearing receptors for somatostatin. Immunology 1987. 62: 655-8.
20. van Dongen JJM. Human T cell differentiation. Basic aspects and their clinical applications (dissertation). Rotterdam, The Netherlands: Erasmus University Rotterdam; 1990.
21. Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992; 103: 1207-14.
22. Aguila MC, Dees WL, Haensly WE, McCann SM. Evidence that somatostatin is localized and synthesized in lymphoid organs. Proc Natl Acad Sci U S A 1991; 88: 11485-9.
23. Fuller PJ, Verity K. Somatostatin gene expression in the thymus gland. J Immunol 1989; 143: 1015-7.
24. Weinstock JV. Neuropeptides and the regulation of granulomatous inflammation. Clin Immunol Immunopathol 1992; 64: 17-22.
25. Weinstock JV, Elliott D. The substance P and somatostatin interferon-gamma immunoregulatory circuit. Ann N Y Acad Sci 1998; 840: 532-39.
26. van Hagen PM, Krenning EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med 1994; 21: 497-502.
27. van Hagen PM, Markusse HM, Lamberts SWJ, Kwekkeboom DJ, Reubi JC, Krenning EP. Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum 1994; 37: 1521-7.
28. ten Bokum AMC, Hofland LJ, de Jong G, Melief MJ, Kwekkeboom DJ, Schonbrunn A, et al. Immunohistochemical localisation of somatostatin receptor SST2a in sarcoid granulomas. Eur J Clin Invest 1999; 29: 630-6.
29. ten Bokum AMC, Melief MJ, Schonbrunn A, van der Ham F, Lindeman J, Hofland LJ, et al. Immunohistochemical localization of somatostatin receptor SST2a in human rheumatoid synovium. J Rheumatol 1999; 26: 532-5.
30. Ferrone D, van Hagen PM, van Koetsveld PM, Zuijderwijk J, Mooy CM, Lichtenauer-Kaligis EGR, et al. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 1999; 140: 373-80
31. Peluso G, Petillo O, Melone MAB, Mazzarella G, Ranieri M, Tajana GF. Modulation of cytokine production in activated human monocytes by somatostatin. Neuropeptides 1996; 30: 443-51.
32. ten Bokum AMC, Lichtenauer-Kaligis EGR, Melief MJ, van Koetsveld PM, Bruns C, van Hagen PM, et al. Somatostatin receptor subtype expression in cells of the rat immune system during adjuvant arthritis. J Endocrinol 1999 161; 167-75.
33. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-31.
34. van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, van den Anker-Lugtenburg PJ, Löwenberg B, et al. Somatostatin and the immune and haematopoietic system: a review. Eur J Clin Invest 1994; 24: 91-9.
35. Mussap CJ, Gerarghty DP, Burcher E. Tachykinin receptors: a radioligand binding perspective. J Neurochem 1993; 60: 1987-2009.
36. Gerard NP, Bao L, Xiao-Ping H, Gerard C. Molecular aspects of the tachykinin receptors. Regul Pept 1993; 43: 21-35.
37. Takahashi K, Tanaka A, Hara M, Nakanishe S. The primary structure and gene organization of human SP and neuromedin K receptors. Eur J Biochem 1992; 204: 1025-33.
38. Lucey DR, Novak JM, Polonis VR, Liu Y, Gartner S. Characterization of substance P binding to human monocytes/macrophages. Clin Diagn Lab Immunol 1995; 1: 330-5.
39. Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol 1997; 159: 5654-60.
40. Lai JP, Douglas SD, Ho WZ. Human lymphocytes express substance P and its receptor. J Neuroimmunol 1998; 86: 80-6.
41. De Giorgio R, Tazzari PL, Barbara G, Stanghellini V, Corinaldesi R. Detection of substance P immunoreactivity in human peripheral leukocytes. J Neuroimmunol 1998; 82: 175-81.
42. Goetzl EJ, Chernov T, Renold F, Payan DG. Neuropeptide regulation of the expression of immediate hypersensitivity. J Immunol 1985; 135(2 Suppl): 802S-5S.
43. Bar-Shavit Z, Goldman R, Stabinsky Y, Gottlieb P, Fridkin M, Teichberg VI, et al. Enhancement of phagocytosis - a newly found activity of substance P residing in its N-terminal tetrapeptide sequence. Biochem Biophys Res Commun 1980; 94: 1445-51.
44. Marasco WA, Showell HJ, Becker EL. Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophil. Biochem Biophys Res Commun 1981; 99: 1065-72.
45. Mazurek N, Pecht I, Teichberg VI, Blumberg S. The role of the N-terminal tetrapeptide in the histamine releasing action of substance P. Neuropharmacology 1981; 20: 1025-7.
46. Hartung HP, Wolters K, Toyka KV. Substance P: binding properties and studies on cellular responses in guinea pig macrophages. J Immunol 1986; 136: 3856-63.
47. Mantyh PW, Johnson DJ, Boehmer CG, Catton MD, Vinters HV, Maggio JE, et al. Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc Natl Acad Sci U S A 1989; 86: 5193-7.
48. Mantyh CR, Gates TS, Zimmerman RP, Welton ML, Passaro EP Jr, Vigna SR, et al. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. Proc Natl Acad Sci U S A 1988; 85: 3235-9.
49. Mapp PI, Walsh DA, Cruwys SC, Kidd BL, Blake DR. Receptors to the neuropeptide substance P in human synovium. Br J Rheumatol 1990; 29 Suppl 1: 44.
50. Walsh DA, Mapp PI, Wharton J, Rutherford RAD, Kidd BL, Revell PA, et al. Localisation and characterisation of substance P binding to human synovial tissue in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 313-7.
51. 1]substance P. J Nucl Med 1996; 37: 108-16.
52. van Hagen PM, Breeman WAP, Reubi JC, Postema PTE, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 1996; 23: 1508-13.
53. Murakami M, Hosoi Y, Negishi T, Kamiya Y, Miyashita K, Yamada M, et al. Thymic hyperplasia in patients with Graves' disease. Identification of thyrotropin receptors in human thymus. J Clin Invest 1996; 98: 2228-34.
54. Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol 1978; 9: 495-515.
55. Hofmann WJ, Moller P, Otto HF. Hyperplasia. In: Givel JC, ed. Surgery of the thymus. Heidelberg, Germany: Springer-Verlag; 1990: 58-70.
56. Tridente G. Immunopathology of the human thymus. Semin Hematol 1985; 22: 56-67.
57. Piantelli M, Maggiano N, Larocca LM, Ricci R, Ranelletti FO, Lauriola L, et al. Neuropeptide-immunoreactive cells in human thymus. Brain Behav Immun 1990; 4: 189-97.
58. Lorton D, Bellinger DL, Felten SY, Felten DL. Substance P innervation of the rat thymus. Peptides 1990; 11: 1269-75.
59. Shigematsu K, Saavedra JM, Kurihara M. Specific substance P binding sites in rat thymus and spleen: in vitro autoradiographic study. Regul Pept 1986; 16: 147-56.
60. Jurjus AR, More N, Walsh RJ. Distribution of substance P positive cells and nerve fibers in the rat thymus. J Neuroimmunol 1998; 90: 143-8.
61. Karalis K, Mastorakos G, Chrousos GP, Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994; 93: 2000-6.
62. Agro A, Stanisz AM. Are lymphocytes a target for substance P modulation in arthritis? Semin Arthritis Rheum 1992; 21: 252-8.
63. Matucci-Cerinic M, Marabini S. Somatostatin treatment for pain in rheumatoid arthritis: a double blind versus placebo study in knee involvement. Med Sci Res 1988; 16: 233-4.
64. Ciocci A, Coari G, Di Franco M, Di Novi MR, Mauceri MT. Intra-articular treatment with Somatostatin 14 in rheumatoid arthritis (in Italian). Clin Ter 1994; 145: 463-7.
65. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325: 1461-7.
66. Bac DJ, van Hagen PM, Postema PTE, ten Bokum AM, Zondervan PE, van Blankenstein M. Octreotide for protein-losing enteropathy with intestinal lymphangiectasia. Lancet 1995; 345: 1639.
67. Reubi JC, Mazzucchelli L, Laissue JA. Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology 1994; 106: 951-9.
68. Eliakim R, Karmeli F, Okon E, Rachmilewitz D. Octreotide effectively decreases mucosal damage in experimental colitis. Gut 1993; 34: 264-9.
69. Agro A, Stanisz AM. Inhibition of murine intestinal inflammation by anti-substance P antibody. Reg Immunol 1993; 5: 120-6.
70. Stanisz AM. Neuroimmunomodulation in the gastrointestinal tract. Ann N Y Acad Sci 1994; 741: 64-72.
71. Donnerer J, Schuligoi R, Stein C, Amann R. Upregulation, release and axonal transport of substance P and calcitonin gene-related peptide in adjuvant inflammation and regulatory function of nerve growth factor. Regul Pept 1993: 46; 150-4.
72. Pernow B. Role of tachykinins in neurogenic inflammation. J Immunol 1985; 135(2 Suppl): 812S-5S.
73. Furchgott RF. Role of endothelium in the responses of vascular smooth muscle. Circ Res 1983; 53: 557-73.
74. Blum AM, Metwali A, Cook G, Mathew RC, Elliott D, Weinstock JV. Substance P modulates antigen-induced, IFN-gamma production in murine schistosomiasis mansoni. J Immunol 1993; 151: 225-33.
75. Lam FY, Ferrell WR. Effects of interactions of naturally-occurring neuropeptides on blood flow in the rat knee joint. Br J Pharmacol 1993; 108: 694-9.
76. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-5.